Identifying Mechanisms of Resistance to Enzalutamide (MDV3100) Treatment in Men with Castration-Resistant Prostate Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Cancer metastases; Prostate cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 24 Sep 2020 Status changed from active, no longer recruiting to completed.
- 25 Apr 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
- 22 Nov 2017 Status changed from recruiting to active, no longer recruiting.